What it is
Thymalin is a mixture of very short peptides taken from the thymus glands of young calves. It was developed in Russia in the early 1980s by Vladimir Khavinson and Vyacheslav Morozov and has been approved for medical use there since 1982. It is not FDA approved in the United States and is sold as a research chemical.
The thymus is a small organ behind your breastbone. It is where T cells, the key fighters and organisers of your immune system, learn to do their job. The thymus starts shrinking early in life, and by your 40s much of its working tissue has been replaced by fat. This is one of the main reasons the immune system weakens with age: you get sick more often, recover more slowly, and respond less well to vaccines.
Thymalin is not a single peptide like BPC-157 or Thymosin Alpha-1. It is a blend, with three key active parts: the two-amino-acid pieces EW and KE and the three-amino-acid piece EDP. These tiny peptides get inside cells and act directly on your DNA to switch immune genes back on.
Thymalin has an unusual amount of human data. Studies lasting 6 to 8 years in 266 elderly patients reported lower death rates and better immune, heart and hormone function. A trial in severe COVID-19 patients found it halved hospital deaths when added to standard care. Almost all of this research comes from Russian institutions and has not been repeated by independent Western groups, so the evidence should be read with that in mind.
Thymalin is a polypeptide complex extracted from the thymus glands of young calves, developed in the early 1980s by Vladimir Khavinson and Vyacheslav Morozov at the St. Petersburg Institute of Bioregulation and Gerontology. It has been approved for medical use in Russia since 1982, is used across CIS countries, and is not FDA approved; in the US and Europe it is available only as a research chemical.
Its relevance rests on thymic involution. The thymus, the site of T cell selection and maturation, begins shrinking early in life, and by the fourth decade most functional tissue has been replaced by adipose. Output of naive T cells falls, contributing to immunosenescence: higher infection rates, slower recovery, blunted vaccine responses, and greater vulnerability to malignancy.
Unlike BPC-157 or Thymosin Alpha-1, Thymalin has no single defined sequence. Three bioactive components have been identified as its key drivers: the dipeptides EW (Glu-Trp) and KE (Lys-Glu) and the tripeptide EDP (Glu-Asp-Pro). These short peptides bind directly to DNA and histone proteins, regulating expression of genes involved in immune function.
The evidence base is large in volume but concentrated in source. Open-label trials spanning 6 to 8 years in 266 elderly patients reported 2.0 to 2.1 fold reductions in mortality and normalisation of immune, cardiovascular, endocrine and nervous system indices. A prospective randomised single-blind trial in severe COVID-19 (Kuznik, Khavinson, et al., 2021) reported hospital mortality of 19.4% versus 40.9% in controls. Nearly all published work originates from Khavinson's group and has not been independently replicated in large Western randomised controlled trials.
How it works
Most peptides work by attaching to a receptor on the outside of a cell, like a key in a lock, and sending a signal inside. Thymalin is different. Its tiny peptide pieces slip into the cell and reach the nucleus, where your DNA is stored. There they attach to the DNA itself and to the proteins that wrap around it.
Think of your immune genes as having a volume knob. As you age, some of those genes get turned down. The instructions are still there, but the body reads them less and less. Thymalin's peptides help turn the volume back up. They do not add new instructions; they restore access to ones your body already has.
Because it works at the gene level, Thymalin affects several parts of the immune system at once:
T cells. It raises the numbers of both helper T cells (CD4+), which organise the response, and killer T cells (CD8+), which destroy infected cells. It also encourages stem cells in the bone marrow to mature into working T cells. In one lab study, a marker of mature T cells rose 6.8 fold.
Natural killer cells. These are first responders that destroy infected or cancerous cells on contact. Thymalin improves their activity.
B cells. These make antibodies. Thymalin helps keep their numbers and function balanced.
Immune signals. It influences messenger molecules such as IL-2 and interferon, and in severe infection it can help calm an overactive immune reaction.
Clean-up cells. It helps neutrophils travel to infection sites and swallow up germs more effectively.
It also supports the production of new blood cells in the bone marrow.
Thymalin does not act through a cell-surface receptor and downstream signalling cascade. Its bioactive short peptides, EW, KE and EDP, cross cell membranes, enter the nucleus and bind selectively to double-stranded DNA sequences and to histone proteins, particularly histone H1/3. The KE peptide, for example, binds selectively to TCGA sequences within genes controlling immune-related cellular processes. The result is epigenetic regulation: restoration of expression in immune genes that have been transcriptionally downregulated with age, rather than introduction of novel signals. This gene-level action explains why Thymalin influences several immune pathways simultaneously.
T cell restoration. Thymalin increases CD4+ helper and CD8+ cytotoxic T cell numbers and restores function lost to age or illness. Part of this is driven by stimulating differentiation of haematopoietic stem cells into mature T lymphocytes. In vitro, Thymalin reduced expression of the stem cell marker CD44 and the intermediate marker CD117 by 2 to 3 fold while increasing CD28, a marker of mature functional T cells, by 6.8 fold (Khavinson, Linkova, et al., 2020).
NK cell activation. Thymalin improves natural killer cell activity, strengthening antigen-independent frontline defence against virus-infected and tumour cells.
B cell balance. It regulates B cell numbers and function, improving antibody responses.
Cytokine modulation. It modulates IL-2 production, which drives T cell proliferation, and interferon, which activates antiviral defences. In states of excessive inflammation it acts as a cytokine antagonist, mitigating cytokine storm.
Phagocytosis. It enhances neutrophil chemotaxis and phagocytic activity, first characterised by Morozov and Khavinson (1997), who isolated the L-Glu-L-Trp dipeptide and showed it activates T cell differentiation, alters cyclic nucleotide composition and modulates cytokine output.
Haematopoiesis. Thymalin supports broader blood cell production in bone marrow. Khavinson, Linkova, et al. (2021) also report expression changes in genes for heat shock proteins, cytokines and fibrinolysis.
What it does
Thymalin rebuilds immune function that has faded with age, illness or medical treatment. In practical terms, it raises the numbers and activity of the cells that find and destroy infections, and it helps the body produce fresh immune cells from the bone marrow.
In the long Russian studies of elderly patients, people treated with Thymalin had 2.0 to 2.4 fold fewer acute respiratory illnesses, fewer signs of ischaemic heart disease, and normalised heart, hormone, immune and nervous system measures. Death rates fell 2.0 to 2.1 fold.
In severe COVID-19, adding Thymalin to standard care led to faster recovery of lymphocyte counts, faster normalisation of inflammation markers such as C-reactive protein, IL-6 and D-dimer, clinical improvement in 80.5% of patients versus 59% in controls, and hospital mortality of 19.4% versus 40.9%.
In rats with transplanted tumours, Thymalin caused tumour growth to stop or reverse in more than half of animals and suppressed growth by 78% in the rest. This is animal data only and does not prove the same in humans.
Users commonly report catching fewer colds after a course, and shorter, milder illness when they do get sick.
Thymalin's core action is immunocorrection: restoring T cell, NK cell, B cell and phagocyte function that has declined through thymic involution, chronic infection, surgery, chemotherapy, radiation or prolonged stress. Because it acts on gene expression rather than maintaining a receptor-mediated signal, the effects persist beyond the dosing window.
In the 6 to 8 year open-label trials in 266 elderly patients (Khavinson and Morozov, 2003; Khavinson and Morozov, 2002), Thymalin alone reduced mortality 2.0 to 2.1 fold versus controls, reduced acute respiratory disease incidence 2.0 to 2.4 fold, lowered incidence of ischaemic heart disease manifestations, and normalised cardiovascular, endocrine, immune and nervous system indices. Combined with Epithalamin, mortality fell 2.5 fold, and annual combined treatment for 6 years produced a 4.1 fold reduction. Epithalamin alone reduced mortality 1.6 to 1.8 fold.
In Kuznik, Khavinson, et al. (2021), a prospective randomised single-blind trial in 80 severe COVID-19 patients (36 Thymalin, 44 placebo), Thymalin 10 mg intramuscularly daily for 10 days plus standard therapy produced 80.5% clinical improvement versus 59%, hospital mortality of 19.4% versus 40.9%, faster resolution of lymphopenia, faster normalisation of C-reactive protein, IL-6 and D-dimer, and better recovery of CD4+, CD8+, B cell and NK cell subpopulations.
In Zhukova, Schikhlyarova, et al. (2018), rats with transplanted sarcoma 45 under activation therapy showed tumour arrest or regression in more than half of animals and 78% growth suppression in the remainder, with increased lymphoproliferative activity in the thymus.
All efficacy data come from a single research group and lack independent replication; the safety record across four decades and thousands of patients is more robust than the efficacy claims.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Restores immune function weakened by age, illness, surgery, chemotherapy, radiation or long-term stressLimited human data
- 2.0 to 2.4 fold fewer acute respiratory infections in long-term studies of elderly patientsLimited human data
- 2.0 to 2.1 fold lower death rate over 6 to 8 years in the same studies, with heart, hormone, immune and nervous system measures returning to normalLimited human data
- Halved hospital deaths in severe COVID-19 when added to standard care (19.4% versus 40.9%)Limited human data
- Fewer signs of ischaemic heart disease and better heart function markersLimited human data
- Supports recovery after surgery, illness, physical trauma, radiation or chemotherapyLimited human data
- Tumour shrinkage or slowed growth in an animal study (not confirmed in humans)Animal or lab only
- Users report more energy and vitality in the weeks after a course, and milder coldsAnecdotal
- Immunocorrection of age-related decline from thymic involution and of secondary immunosuppression following chronic infection, surgery, chemotherapy or radiationLimited human data
- Increased CD4+ and CD8+ T cell numbers and function, driven partly by 6.8 fold upregulation of CD28 on differentiating haematopoietic stem cells in vitroLimited human data
- Enhanced NK cell activity, B cell regulation, IL-2 and interferon modulation, and neutrophil chemotaxis and phagocytosisAnimal or lab only
- 2.0 to 2.1 fold mortality reduction versus controls over 6 to 8 years in 266 elderly patients; 2.5 fold when combined with Epithalamin and 4.1 fold with 6 years of annual combined coursesLimited human data
- 2.0 to 2.4 fold reduction in acute respiratory disease incidence and reduced ischaemic heart disease manifestationsLimited human data
- Hospital mortality of 19.4% versus 40.9% and 80.5% versus 59% clinical improvement in severe COVID-19 (Kuznik, Khavinson, et al., 2021), with faster normalisation of CRP, IL-6, D-dimer and lymphocyte subpopulationsLimited human data
- Cytokine antagonist activity in excessive inflammation, mitigating cytokine stormLimited human data
- Support of haematopoiesis beyond the immune lineageAnimal or lab only
- Antitumour activity in transplanted sarcoma 45 in rats: regression in more than half of animals, 78% growth suppression in the remainderAnimal or lab only
- Absence of hormonal alteration, dependency or immune overstimulation across four decades of clinical useLimited human data
What to expect
Thymalin is not a peptide you feel working straight away. There are no published studies tracking how people feel on day 3 versus day 7. The clinical data measures blood markers and long-term outcomes.
Based on that data, immune markers such as T cell counts, the CD4/CD8 ratio and NK cell activity start improving during the 10-day course and keep improving in the weeks after. In the COVID-19 trial, inflammation markers including C-reactive protein, IL-6 and D-dimer normalised faster in the Thymalin group during treatment.
The bigger benefits, such as fewer infections and the longevity findings, appeared over months to years of repeated annual courses. The effect is gradual and builds up over time.
Users commonly report more energy and general vitality in the days and weeks after a course. Some feel mild tiredness in the first 2 to 3 days. Fewer and milder colds is the most consistently reported benefit, especially when the cycle is run before cold and flu season. Some also report faster recovery from training and quicker wound healing, though these are secondary effects.
Because you run a short 5 to 10 day course and then stop for months, the experience is very different from daily peptides like BPC-157. The effects continue after the injections finish.
Side effects are usually minimal: mild redness or discomfort where you inject, and slight fatigue early in the cycle. Mild nausea or headache are rare and usually linked to injection technique or dehydration.
No published dose-finding or timeline studies track patient-reported outcomes during a Thymalin course; the clinical literature measures laboratory indices and mortality over months to years.
From the available data, improvements in immune markers (T cell counts, CD4/CD8 ratio, NK cell activity) begin within the 10-day course and continue to improve in the following weeks. In Kuznik, Khavinson, et al. (2021), C-reactive protein, IL-6 and D-dimer normalised faster than in controls during the treatment period, alongside faster recovery from lymphopenia.
The geroprotective and infection-prevention outcomes in the 6 to 8 year trials emerged cumulatively over repeated annual courses. Because the mechanism is epigenetic rather than dependent on sustained plasma levels, effects persist and build after the peptide has cleared; the cycle functions as a periodic reset rather than maintenance dosing.
In practice, users report increased energy and vitality in the weeks after a course, with a subset noting mild fatigue during the first 2 to 3 days, attributed to immune recalibration. Reduced frequency and severity of respiratory infections is the most consistent report, particularly when courses precede cold and flu season. Improved training recovery and wound healing are reported as secondary effects.
Adverse effects are minimal. Published trials, including the 80-patient COVID-19 study, reported no adverse effects attributable to Thymalin, no systemic toxicity, no hormonal alterations, no dependency or withdrawal, and no immune overstimulation. Users report injection-site redness or discomfort and transient early fatigue as the common issues; mild nausea and headache are rare and usually attributed to technique or dehydration.
Reconstitution and dosing
The standard course is 10 mg once a day for 10 days in a row, then a break of months. Most people run 1 to 2 courses a year. A full course uses 100 mg, which is 10 vials of 10 mg.
To prepare a vial, add 1 mL of bacteriostatic water to a 10 mg vial. This gives 10 mg per mL. Draw the whole 1 mL for a 10 mg dose, or 0.5 mL for a 5 mg dose. At 10 mg a day each vial lasts one day; at 5 mg a day each vial lasts two days. Keep the mixed vial in the fridge at 2 to 8 degrees Celsius and use it within the cycle.
Inject once a day, ideally in the morning, under the skin or into a muscle. The original studies used muscle injections; in practice most people now inject under the skin at the same dose. No research has compared the two routes.
You do not need to fast. Thymalin does not interact with food or with growth hormone the way GH peptides do.
Different goals use slightly different plans:
Immune restoration: 10 mg daily for 10 days, repeated every 6 to 12 months.
Anti-ageing: 10 mg daily for 10 days, once or twice a year.
Recovery after illness: 5 to 10 mg daily for 5 to 10 days, starting once the acute phase has passed.
Seasonal prevention: 5 to 10 mg daily for 5 to 10 days, run 2 to 4 weeks before cold and flu season.
No human studies have compared different dose levels, so these plans are based on the doses used in the trials and on practice patterns, not on dose-finding research.
Published trials, including the 6 to 8 year longevity studies and the COVID-19 trial, used 10 mg daily intramuscularly for 10 consecutive days, repeated annually or twice yearly. No dose-finding studies comparing dose levels in humans exist; practical protocols mirror the studied regimen and clinical practice patterns.
Standard protocol: 10 mg daily, subcutaneous or intramuscular, for 10 consecutive days, 1 to 2 cycles per year. Course total 100 mg (10 vials of 10 mg).
Reconstitution: 10 mg vial with 1 mL bacteriostatic water gives 10 mg per mL. Draw 1 mL for 10 mg or 0.5 mL for 5 mg. Each vial covers one day at 10 mg or two days at 5 mg. Store reconstituted vials at 2 to 8 degrees Celsius and use within the cycle duration.
By application: immune restoration, 10 mg daily for 10 days every 6 to 12 months; geroprotection, 10 mg daily for 10 days, annual or twice-yearly; post-illness recovery, 5 to 10 mg daily for 5 to 10 days beginning after the acute phase; seasonal prevention, 5 to 10 mg daily for 5 to 10 days, typically 2 to 4 weeks before cold and flu season.
Administration is once daily, preferably in the morning. The pulsed structure, short intensive courses separated by months, reflects the persistence of epigenetic changes after the peptide has cleared. The original research used intramuscular injection; in practice subcutaneous administration at identical doses has become common for self-administration. No published research compares the two routes.
No fasting is required; Thymalin does not interact with food absorption or GH signalling. When stacked with Epithalamin per the longevity trials, both are run concurrently at 10 mg daily for 10 days, 1 to 2 times per year.
Standard, 10 mg vial
Mix with 1 mL (100 units) of bacteriostatic water.
10 mg/mL · 100 mcg per unit
Cycle: 10 consecutive days, 1 to 2 cycles per year · Frequency: Once daily, preferably in the morning
| When | Dose | Draw | How often |
|---|---|---|---|
| Standard | 10 mg | 100 units | once daily |
10 mg in 1 mL is 10 mg/mL, or 100 mcg per unit. Draw 100 units (1 mL) for 10000 mcg.
Who should avoid it
- Anyone with a known allergy to thymus peptides or to products made from cows. Thymalin comes from calf thymus glands, so do not use it if you react to bovine products.
- Anyone who has had an organ transplant and takes drugs to suppress the immune system. Thymalin pushes the immune system in the opposite direction and could raise the risk of rejection.
- People with an active autoimmune condition such as rheumatoid arthritis, lupus, or multiple sclerosis should be very careful. Thymalin boosts immune activity, which could make a flare worse. Talk to a doctor first.
- People with active cancer or a recent cancer diagnosis should speak to their oncologist before use. Animal data suggests an anti-tumour effect, but there is no human data for this use.
- Anyone who is pregnant or breastfeeding. There is no safety data.
- Anyone taking any kind of immunosuppressant medication. Thymalin may cancel out its effect. Do not combine without a doctor's supervision.
- Known hypersensitivity to thymic peptides or bovine-derived products; Thymalin is extracted from calf thymus.
- Organ transplant recipients on immunosuppressive therapy. Thymalin restores T cell production and function and could counteract immunosuppression, increasing rejection risk.
- Active autoimmune disease (rheumatoid arthritis, lupus, multiple sclerosis and similar), particularly during a flare. Upregulation of immune gene expression, CD4+ and CD8+ expansion and cytokine modulation may theoretically worsen autoreactive activity.
- Active or recent malignancy. Zhukova, Schikhlyarova, et al. (2018) reported tumour regression in a rat sarcoma 45 model, but no human data exists for this application; oncologist review is required.
- Pregnancy or breastfeeding, for which no safety data exists.
- Concurrent immunosuppressant drugs of any class. This is the only well-characterised interaction; Thymalin does not compete for receptors or metabolic pathways, so no other established drug interactions are described.
Side effects
- Redness or mild soreness where the injection was given. This is normal for any injection.
- Slight tiredness during the first 2 to 3 days of a course. Users say this passes on its own.
- Mild nausea (rare).
- Headache (rare). Users usually put this down to poor injection technique or not drinking enough water.
- Most users report no side effects at all. The published studies reported no significant adverse effects.
- Injection site erythema or mild discomfort, consistent with any subcutaneous or intramuscular administration.
- Transient fatigue during the first 2 to 3 days of a cycle, reported by a subset of users and attributed in practice to immune recalibration.
- Mild nausea (rare).
- Headache (rare), generally attributed to injection technique or dehydration rather than the compound.
- Published research reported no significant adverse effects: the 6 to 8 year clinical studies noted an absence of any side reactions, and the COVID-19 trial of 80 patients reported no adverse effects attributable to Thymalin. Clinical use in Russia over four decades has shown no hormonal alterations, no dependency or withdrawal effects, and no immune overstimulation.
What the evidence shows
Thymalin has more human data than most research peptides, but nearly all of it comes from one Russian research group, and none of it has been repeated by independent Western teams. That is the single most important thing to understand about the evidence.
The biggest study is Khavinson and Morozov (2003). It followed 266 elderly patients for 6 to 8 years. Deaths fell 2.0 to 2.1 fold in people given Thymalin compared with controls. Combined with Epithalamin, a pineal gland peptide, deaths fell 2.5 fold, and yearly treatment with both for 6 years cut deaths 4.1 fold. Chest infections dropped 2.0 to 2.4 fold. The study was open-label, meaning nobody was blinded, so the results need confirming elsewhere. Khavinson and Morozov (2002) reported the same group of patients.
The best-designed study is the COVID-19 trial by Kuznik, Khavinson, et al. (2021). 36 severe COVID-19 patients got Thymalin 10 mg by intramuscular injection daily for 10 days plus standard care, and 44 got standard care plus placebo. 80.5% of the Thymalin group improved versus 59% of controls, and hospital deaths were 19.4% versus 40.9%. Inflammation markers also settled faster. It was small (80 patients), single centre and single-blind.
Lab work supports the mechanism. Khavinson, Linkova, et al. (2020) showed Thymalin pushed human stem cells to mature into T cells in a dish, with a 6.8 fold rise in a marker of mature T cells. Morozov and Khavinson (1997) and Khavinson, Linkova, et al. (2021) described how its peptides work on genes. Zhukova, Schikhlyarova, et al. (2018) found tumour shrinkage in more than half of rats with transplanted tumours and 78% slower growth in the rest, but rat tumours are not human cancer.
What to take from this: the safety record is reassuring, the mechanism is plausible, and the results are striking. Treat the longevity claims with caution until someone else repeats them.
The Thymalin literature is large in volume but concentrated almost entirely in Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology, with no independent Western replication.
Longevity. Khavinson and Morozov (2003), Neuroendocrinology Letters, reported 6 to 8 year open-label trials in 266 elderly patients comparing Thymalin, Epithalamin, the combination and controls. Thymalin alone reduced mortality 2.0 to 2.1 fold; Epithalamin alone 1.6 to 1.8 fold; the combination 2.5 fold; annual combined treatment for 6 years 4.1 fold. Acute respiratory disease incidence fell 2.0 to 2.4 fold and cardiovascular, endocrine, immune and nervous system indices normalised. Khavinson and Morozov (2002), Advances in Gerontology, reported the same cohort. The design was unblinded and single-institution; the 4.1 fold figure is an extraordinary claim awaiting confirmation.
COVID-19. Kuznik, Khavinson, et al. (2021) ran a prospective randomised single-blind controlled trial at Chita State Medical Academy Hospital: 36 patients received Thymalin 10 mg intramuscularly daily for 10 days plus standard therapy, 44 received standard therapy plus placebo. Clinical improvement was 80.5% versus 59%; hospital mortality 19.4% versus 40.9%. Thymalin patients showed faster resolution of lymphopenia, faster normalisation of C-reactive protein, IL-6 and D-dimer, and better recovery of CD4+, CD8+, B cell and NK cell subpopulations. Limitations: 80 patients, single centre, single-blind, pandemic-era protocols.
Mechanism. Khavinson, Linkova, et al. (2020) showed in vitro that Thymalin reduced CD44 and CD117 expression 2 to 3 fold and increased CD28 6.8 fold in human haematopoietic stem cells, indicating differentiation toward mature T lymphocytes. Morozov and Khavinson (1997) isolated L-Glu-L-Trp and demonstrated T cell differentiation, cyclic nucleotide shifts, IL-2 and interferon modulation, and enhanced neutrophil chemotaxis and phagocytosis. Khavinson, Linkova, et al. (2021) reviewed the nuclear penetration of EW, KE and EDP and their selective binding to DNA sequences and histone H1/3, altering expression of immune, heat shock protein, cytokine and fibrinolysis genes.
Antitumour. Zhukova, Schikhlyarova, et al. (2018) reported growth arrest or regression in more than half of rats bearing transplanted sarcoma 45 under activation therapy, with 78% growth suppression in the remainder. Khavinson (2002) reviewed geroprotective and anticarcinogenic associations.
The safety record across four decades is reassuring; efficacy, particularly the mortality data, requires independent replication.
User reports
From public forums
Not many people talk about Thymalin compared with BPC-157 or Thymosin Alpha-1, so reports are thinner. What follows is anecdotal and does not carry the weight of published research.
The most consistent report is fewer colds. Users who run a course before cold and flu season say they get sick less often, and when they do, it is shorter and milder. This matches the clinical finding of fewer respiratory infections.
Many users report more energy and a general sense of wellbeing in the weeks after a course. Some feel mildly tired during the first 2 to 3 days of the cycle itself and put this down to the immune system adjusting. A few report faster recovery from training and quicker wound healing, though these are secondary to the immune effects.
Because Thymalin is run as a short 5 to 10 day course rather than daily for months, users describe the effects as building and lasting over the months that follow rather than being felt day to day. Most report little or no side effects beyond mild injection site soreness.
User discussion of Thymalin is limited relative to BPC-157 or Thymosin Alpha-1, and all of the following is anecdotal.
The most consistently reported outcome is reduced frequency of colds and respiratory infections when cycles are timed before cold and flu season, with shorter and milder illness when infection does occur. This tracks the 2.0 to 2.4 fold reduction in acute respiratory disease reported in the longevity cohort.
Users commonly report improved energy and vitality in the weeks following a cycle. A subset report mild fatigue in the first 2 to 3 days of a course, attributed in practice to immune recalibration. Some report improved training recovery and wound healing as secondary effects.
In practice, users frequently run Thymalin concurrently with Epithalon in annual courses, mirroring the combination that produced the 4.1 fold mortality reduction in Khavinson and Morozov (2003), and some pair it with Thymosin Alpha-1 on the rationale that Thymalin acts at the gene expression level while Thymosin Alpha-1 activates existing cells via Toll-like receptors. Neither combination has independent published support.
Users have largely shifted from the intramuscular route used in the trials to subcutaneous injection at the same doses; no published comparison of the two routes exists. Reported side effects are minimal: injection site discomfort and transient early fatigue, with serious events essentially absent.
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
This is the pairing used in the long-term longevity studies. Thymalin supports the immune system while Epithalamin, a pineal gland peptide, supports the pineal gland and melatonin. Yearly treatment with both for 6 years cut deaths 4.1 fold in the published study. Both are run as 10 mg daily for 10 days at the same time, 1 to 2 times per year.
The combination studied in Khavinson and Morozov (2003): Thymalin addresses thymic immune restoration while Epithalamin addresses pineal function and melatonin regulation. Annual combined treatment for 6 years produced a 4.1 fold mortality reduction versus 2.0 to 2.1 fold for Thymalin alone. Both are run concurrently at 10 mg daily for 10 days, 1 to 2 times per year. No independent replication exists.
Both support the immune system but in different ways. Thymalin helps the body make and restore immune cells; Thymosin Alpha-1 switches on the immune cells already present. Users run them together for broader immune support. No study has tested this pairing.
Complementary mechanisms: Thymalin acts at the gene expression level by binding DNA and histones to restore immune gene function, while Thymosin Alpha-1 acts at the receptor level via Toll-like receptors TLR-2 and TLR-9 on immune cells. No published research has examined the combination.
No known interaction. Growth hormone peptides need to be taken on an empty stomach; Thymalin does not. Keep each on its own schedule.
No interaction concerns; entirely separate mechanisms. GH secretagogues require fasting and Thymalin does not, so each is kept to its own schedule.
No known interaction. Ipamorelin needs fasting; Thymalin does not. Run them on separate schedules.
No interaction concerns. Ipamorelin acts on GH release and requires fasting; Thymalin does not affect GH signalling. Separate schedules.
No known interaction. Sermorelin should be taken fasted; Thymalin can be taken with food. Keep them separate.
No interaction concerns. Sermorelin requires fasting; Thymalin does not interact with food absorption or GH pathways.
No known interaction. Thymalin works on the immune system and BPC-157 on tissue repair. They can be used at the same time if both immune weakness and an injury are being addressed.
No interaction concerns. Thymalin targets immune restoration while BPC-157 targets tissue repair; the two can run concurrently when immune weakness and injury recovery coincide.
No known interaction. TB-500 helps tissue heal; Thymalin helps the immune system. They can be run together.
No interaction concerns. TB-500 addresses tissue repair and Thymalin immune function; concurrent use is straightforward.
- TRT
No known interaction. Thymalin can be used alongside testosterone replacement therapy.
No interaction concerns; Thymalin can run alongside testosterone replacement therapy without adjustment.
Common questions
How is Thymalin different from Thymosin Alpha-1?
Both come from the thymus, but they are different substances. Thymosin Alpha-1 is one single peptide that switches on immune cells from the outside. Thymalin is a mix of several tiny peptides that get inside the cell and turn immune genes back up. Thymosin Alpha-1 has more Western data and is approved in over 35 countries. Thymalin has four decades of Russian data but no Western approval. They can be used together.
Thymosin Alpha-1 is a single 28 amino acid peptide that activates immune cells via cell-surface Toll-like receptors. Thymalin is a complex of short peptides (EW, KE, EDP) that penetrate the nucleus and regulate gene expression by binding DNA and histone proteins. Thymosin Alpha-1 has broader Western clinical data and approval in over 35 countries; Thymalin has extensive Russian clinical data spanning four decades but no Western regulatory approval. The two are complementary.
Why is the dosing schedule so different from other peptides?
Most peptides are taken every day for weeks or months. Thymalin is taken as a short 10-day course with months off between courses. That is how it was used in the studies, including the 6 to 8 year longevity trial. The idea is that its effect on genes carries on after the peptide has left the body, so a constant level is not needed.
The pulsed protocol mirrors the published clinical studies, particularly the 6 to 8 year longevity trial. Thymalin's short peptides alter gene expression, and those epigenetic changes persist after the compound clears, so the goal is a periodic immune reset rather than a maintained plasma concentration.
Can Thymalin be used with an autoimmune condition?
Be very careful. Thymalin boosts the immune system. If your immune system is already attacking your own body, boosting it could make things worse. Speak to your doctor first, especially during a flare of rheumatoid arthritis, lupus, or multiple sclerosis.
Extreme caution is warranted. Thymalin stimulates and restores immune function, which could theoretically exacerbate autoreactive activity in conditions such as rheumatoid arthritis, lupus, or multiple sclerosis, particularly during an active flare. Physician review is required.
Does Thymalin cause cancer?
No study has shown that. In a rat study, Thymalin actually shrank transplanted tumours in more than half of the animals and slowed growth by 78% in the rest. The longevity studies also mentioned anti-cancer activity as a benefit. Even so, anyone with active cancer should check with their oncologist because Thymalin boosts immune activity.
No study has shown carcinogenic effects. Zhukova, Schikhlyarova, et al. (2018) reported tumour regression in more than half of rats with transplanted sarcoma 45 and 78% growth suppression in the remainder, and the longevity literature notes anticarcinogenic activity associated with immune restoration. Because Thymalin stimulates immune cell production and activity, active malignancy still warrants oncologist consultation.
Is the research reliable given that it mostly comes from Russia?
It is a fair question. Almost all the research comes from one group in St. Petersburg. The papers are peer-reviewed and listed on PubMed, but no Western group has repeated them. The 2021 COVID-19 trial is the best-designed study. The longevity numbers are impressive but need independent confirmation.
The bulk of the literature originates from a single group at the St. Petersburg Institute of Bioregulation and Gerontology. The studies are peer-reviewed and PubMed-indexed but lack independent Western replication. The 2021 COVID-19 trial is the most rigorous, with a randomised controlled design. The longevity findings are extraordinary claims that require independent replication before confidence is warranted.
When should a Thymalin cycle be timed?
For colds and flu, run a course 2 to 4 weeks before the season starts, usually early autumn. For longevity, run a course once or twice a year at the same times each year. For recovery after illness or surgery, start once the worst has passed.
For seasonal prevention, 2 to 4 weeks before cold and flu season, typically early autumn. For geroprotective protocols following the Khavinson model, annual or twice-yearly cycles at consistent times of year. For post-illness or post-surgical recovery, begin after the acute phase has resolved.
Does injection route matter?
The studies used injections into muscle. Users mostly inject under the skin instead because it is easier, using the same dose. No study has compared the two for Thymalin.
The original clinical research used intramuscular injection. In practice users have largely shifted to subcutaneous administration at identical doses for ease of self-administration. No published research compares the two routes for Thymalin specifically.
References
- Khavinson V, Morozov V. Peptides of pineal gland and thymus prolong human life. Neuroendocrinol Lett. 2003;24(3-4):233-240.
- Khavinson VKh, Morozov VG. Geroprotective effect of thymalin and epithalamin. Adv Gerontol. 2002;10:74-84.
- Kuznik B, Khavinson V, Shapovalov K, et al. Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients. Adv Gerontol. 2021;11(4):368-376.
- Morozov VG, Khavinson VKh. Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int J Immunopharmacol. 1997;19(9-10):501-505.
- Khavinson VKh. Peptides and Ageing. Neuroendocrinol Lett. 2002;23 Suppl 3:11-144.
- Khavinson VKh, Linkova NS, Chalisova NI, Ivko OM. The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity. Biol Bull Rev. 2021;11(4):377-382.
- Khavinson VKh, Linkova NS, Kvetnoy IM, et al. Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bull Exp Biol Med. 2020;170(1):118-122.
- Khavinson VKh, Kuznik BI, Trofimova SV, et al. Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19. Stem Cell Rev Rep. 2021;17(1):285-290.
- Zhukova GV, Schikhlyarova AI, Barteneva TA, et al. Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo. Bull Exp Biol Med. 2018;165(1):80-83.
This entry was written from additional reference material. Units are recomputed from the stated protocol.